NASDAQ:THAR Tharimmune Q4 2024 Earnings Results & Report $2.11 0.00 (0.00%) As of 10/12/2026 Tharimmune reported Q4 2024 earnings on March 25, 2025. The company reported EPS of -$2.02. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 25, 2025TimeAfter Market ClosesConference Call DateMarch 26, 2025Conference Call8:00 AM ET Tharimmune EPS ResultsActual EPS-$2.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersTharimmune Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Tharimmune Q4 2024 Earnings FAQ Did Tharimmune beat earnings estimates for Q4 2024? Tharimmune (NASDAQ:THAR) reported earnings of -$2.02 per share for Q4 2024. The report was announced on Tuesday, March 25, 2025. Tharimmune Earnings HeadlinesTharimmune Inc.May 13, 2026 | wsj.comTharimmune Rebrands as Canton Strategic Holdings, Updates TickerFebruary 18, 2026 | tipranks.comElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he says is the same size Nvidia was a decade ago. The company holds 150 patents protecting its core technology, and Brown believes Elon Musk could soon drive major demand for it. A key catalyst is set for November 11.October 14 at 1:00 AM | Brownstone Research (Ad)Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury StrategyFebruary 17, 2026 | prnewswire.comCatherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio ImpactFebruary 11, 2026 | finance.yahoo.comTharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating OfficerFebruary 6, 2026 | prnewswire.comSee More Tharimmune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tharimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tharimmune and other key companies, straight to your email. Email Address About TharimmuneTharimmune (NASDAQ:THAR) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development activities center on treatments intended to address conditions with significant unmet medical needs. Tharimmune’s lead development program, TH104, is an intranasal film formulation of aprepitant, a neurokinin-1 receptor antagonist. The program is being developed for chronic pruritus, including itching associated with cholestatic liver disease and other conditions. The company is also evaluating additional therapeutic opportunities involving inflammatory and immunological disorders. Tharimmune is based in the United States and operates primarily as a biotechnology research and development company. Its products remain in clinical or precommercial development, and the company’s future activities depend on advancing its pipeline through clinical testing and regulatory review.View Tharimmune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
